Archive for August 2023
Firebrick Phase 3 Trial fully recruited with 500 subjects
09 Aug 2023
Firebrick Pharma is pleased to announce that its Phase 3 trial of Nasodine® Nasal Spray in the treatment for the common cold has successfully completed recruitment, with 500 subjects enrolled. “Subject to availability of the complete efficacy data and timely completion of the statistical analysis, we expect to report headline results of the trial by…
Nasodine COVID-19 Trial Achieves Primary Endpoint
07 Aug 2023
Highlights Firebrick Pharma Limited is pleased to announce that its Phase 2 trial of Nasodine® Nasal Spray in COVID-19 achieved its primary endpoint. The primary endpoint was the reduction in viral load of SARS-CoV-2 over 4 days, based on culturable virus from throat and nasal swabs. Nasodine treatment resulted in 100% reduction by day 4,…